Intervacc announces the outcome of the rights issue

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, RELEASE OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE REFER TO OMPIRTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Stockholm, 24 February 2025

The subscription period for the rights issue in Intervacc AB (publ) (”Intervacc” or the ”Company”) ended on 21 February 2025. 221,671,338 shares, corresponding to approximately 84 percent of the rights issue, were subscribed for by exercise of subscription rights and 82,205,104 shares, corresponding to approximately 31 percent of the rights issue, were subscribed for without subscription rights. The rights issue is thus oversubscribed and guarantee commitments received in connection with the rights issue will not be used. The total subscription rate in the rights issue amounts to approximately 115 percent, which entails that Intervacc will receive proceeds of approximately SEK 225 million before deduction of issue costs.

The rights issue includes 265,076,924 new shares. The subscription price was SEK 0.85 per share. Through the rights issue, the Company will receive approximately SEK 225 million before deduction of issue costs, which amount to approximately SEK 31 million. Through the rights issue, the Company’s share capital will increase by SEK 53,015,384.80, from SEK 15,147,252.80 to SEK 68,162,637.60 and the total number of shares will increase by 265,076,924, from 75,736,264 shares to 340,813,188 shares. Existing shareholders who do not participate in the rights issue will have their shareholdings diluted with approximately 78 percent.

HealthCap IX Investments AB (“**HealthCap**”) has subscribed for 57,877,316 new shares by exercise of subscription rights in the rights issue, and has been allotted 30,357,978 new shares through subscription without subscription rights. HealthCap will thus hold approximately 26 per cent of the total number of shares in the Company following the rights issue.

Allotment of shares subscribed for without subscription rights has been made in accordance with the principles outlined in the prospectus. Around 25 February 2025, a settlement note will be sent to those who have received allotment of shares as confirmation of the allotment of shares subscribed for without subscription rights. No confirmation will be sent to subscribers who received no allotment. Payment for subscribed and allocated shares is to be made in cash in accordance with the instructions on the settlement note sent to the subscriber. Nominee-registered shareholders will receive a notification of allotment in accordance with the respective nominee's procedures.

The first day of trading in the new shares on Nasdaq First North Growth Market is expected to be on or around 6 March 2025.

Advisors

In conjunction with the rights issue, the Company has engaged Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Bookrunner, and Cirio Advokatbyrå AB as legal advisor.

For more information please contact:

Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600
E-mail: jonas.sohlman@intervacc.se

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 19.55 CET on February 24, 2025.

About Intervacc
Intervacc AB (publ) is a Swedish company within animal health developing vaccines for animals. The Company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is on listed the Nasdaq First North Growth Market.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares, paid subscribed shares, subscription rights or other securities in the Company ("**Securities**"). No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for shares in the Company has only been made through the prospectus and the supplementary prospectus that the Company has published in an authorised manner.

The information in this press release may not be announced, published or distributed, directly or indirectly, in or into the United States of America (including its territories and provinces, any state of the United States and the District of Columbia, the "**USA**"), Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where doing so might be unlawful, subject to legal restrictions or require measures other than those required under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities laws.

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the USA. No Securities have been, nor will they be, registered under the U.S. Securities Act of

1933, as amended (the "**Securities Act**") or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. The Securities have not been, nor will they be, approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the offer or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.

Within the European Economic Area ("**EEA**"), no public offering of Securities is made in other countries than Sweden. In other member states of the European Union, such offering of Securities may only be made in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "**Prospectus Regulation**"). In other states within the EEA which have implemented the Prospectus Regulation in its national legislation, any such offer of Securities may only be made in accordance with an applicable exemption under the Prospectus Regulation and in accordance with any relevant implementing measure. In other states within the EEA which have not implemented the Prospectus Regulation in its national legislation, any such offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the Securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the Prospectus Regulation which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release is not a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. This press release identifies neither nor purports to identify risks (direct or indirect) that may be associated with an investment in the Securities. Any investment decision should, in order for an investor to fully understand the potential risks and rewards associated with the decision to participate in the Rights Issue, be made solely on the basis of the information contained in the prospectus and the supplementary prospectus.

The Company considers that it conducts protection-worthy activities under the Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar) (the "**FDI Act**"). This means that investors who achieve certain influence in the

Company may need to notify investments in the Company to and obtain approval from the Inspectorate for Strategic Products (Sw. Inspektionen för strategiska produkter) ("**ISP**") before such an investment can be conducted. Each investor should consult with an independent legal advisor as to the possible application of the FDI Act in relation to the Rights Issue for the individual investor. For more information, please visit ISP's website, www.isp.se, or contact the Company.

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

Date Created
2025-02-24